This is the authors' abstract. We don't add key points for this paper.
In recent decades, there has been a significant increase in the frequency of immune-related adverse event (irAE)–associated renal injury due to the dramatic advances of anti-cancer immunotherapy. Of these, the most popular renal lesion is irAE-associated tubulointerstitial nephritis (irAE-TIN). Since the COVID-19 pandemic, we also often experience cases with
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fujomoto et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: